Effects of subclinical XXXX on the heart.

@entity1 @entity1375 @entity583 @entity731 @entity1955 @entity1378 @entity6145 @entity299 @entity453 @entity943 @entity65 @entity1374
BACKGROUND: Mounting evidence indicates that subclinical @entity1374 has important clinical effects and prognostic implications, supporting the view that it is not a compensated biochemical change sensu strictu. PURPOSE: To review clinical information on the effects of subclinical @entity1374 on the heart. DATA SOURCES: English-language articles identified from files and a MEDLINE search (1970-September 2001), references of relevant articles, textbooks, and meeting abstracts. STUDY SELECTION: Reports on the effects of @entity1375 and @entity1378 on the cardiovascular system in @entity1 . DATA EXTRACTION: Data on cardiac structure and performance, @entity943 , and risk for @entity453 were independently assessed by all authors and summarized. DATA SYNTHESIS: @entity1375 is associated with impaired left ventricular diastolic function at rest, @entity299 on effort, and enhanced risk for @entity731 and @entity583 . Subclinical @entity1378 is associated with increased heart rate, @entity943 , increased left ventricular mass with marginal concentric remodeling, impaired ventricular relaxation, reduced exercise performance, and increased risk for @entity65 . All abnormalities were reversed by restoration of euthyroidism ( @entity1375 ) or were blunted by beta-blockade and tailoring of the @entity1955 dose ( @entity1378 ). CONCLUSION: The heart responds to the minimal but persistent changes in circulating @entity6145 levels typical of subclinical @entity1374 . Thus, the condition is not a compensated biochemical change sensu strictu, and timely treatment should be considered in an attempt to avoid adverse cardiovascular effects.
